Examples of using Trabectedin in English and their translations into Danish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Renal elimination of unchanged trabectedin in humans is low less than 1.
Yondelis 0.25 mg powder for concentrate for solution for infusion Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin.
Trabectedin has been administered for 6
Caution should be taken if medicinal products associated with hepatotoxicity are administered concomitantly with trabectedin, since the risk of hepatotoxicity may be increased.
are administered concomitantly with trabectedin, since the risk of rhabdomyolysis may be increased.
Preclinical data indicate that trabectedin has limited effect on the cardiovascular,
Trabectedin has been shown to exert antiproliferative in vitro
The efficacy and safety of trabectedin is based in a randomised trial in patients with locally advanced
In this trial trabectedin was administered either at 1.5 mg/ m2 as a 24-hour intravenous infusion every 3 weeks
of total radioactivity in the urine after a single dose of 14 C-labelled trabectedin indicates that renal impairment has little influence on the elimination of trabectedin
Since trabectedin is metabolised mainly by CYP3A4,
The active substance in Yondelis, trabectedin, is an anticancer medicine.
The safety and efficacy of trabectedin in paediatric patients have not yet been established.
Trabectedin can have genotoxic effects.
The excretion of trabectedin in milk has not been studied in animals.
Trabectedin is genotoxic both in vitro
Trabectedin must not be used in patients with CPK> 2.5 ULN see section 4.2.
It contains the active substance trabectedin.
Effects of other substances on trabectedin.
Preclinical data have demonstrated that trabectedin is a substrate to P-gp.